Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction

• Main Authors: Yuya Ide, MD, Takahiro Horie, MD, PhD, Naritatsu Saito, MD, PhD, Shin Watanabe, MD, PhD, Chiharu Otani, MD, Yui Miyasaka, BSc, Yasuhide Kuwabara, MD, PhD, Tomohiro Nishino, MD, PhD, Tetsushi Nakao, MD, PhD, Masataka Nishiga, MD, PhD, Hitoo Nishi, MD, PhD, Yasuhiro Nakashima, MD, PhD, Fumiko Nakazeki, MD, PhD, Satoshi Koyama, MD, PhD, Masahiro Kimura, MD, Shuhei Tsuji, MD, Randolph Ruiz Rodriguez, MD, Sijia Xu, MD, Tomohiro Yamasaki, MD, Toshimitsu Watanabe, MD, Masamichi Yamamoto, PhD, Motoko Yanagita, MD, PhD, Takeshi Kimura, MD, PhD, Akira Kakizuka, MD, PhD, Koh Ono, MD, PhD
• Format: Article
• Language: English
• Published: Elsevier 2019-10-01
• Series: JACC: Basic to Translational Science
• Online Access: http://www.sciencedirect.com/science/article/pii/S2452302X19301822
• ISSN: 2452-302X

Summary: No effective treatment is yet available to reduce infarct size and improve clinical outcomes after acute myocardial infarction by enhancing early reperfusion therapy using primary percutaneous coronary intervention. The study showed that Kyoto University Substance 121 (KUS121) reduced endoplasmic reticulum stress, maintained adenosine triphosphate levels, and ameliorated the infarct size in a murine cardiac ischemia and reperfusion injury model. The study confirmed the cardioprotective effect of KUS121 in a porcine ischemia and reperfusion injury model. These findings confirmed that KUS121 is a promising novel therapeutic agent for myocardial infarction in conjunction with primary percutaneous coronary intervention. Key Words: ATP, ER stress, KUS121, myocardial infarction